354 related articles for article (PubMed ID: 31668632)
1. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
2. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
3. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
4. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
5. Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto M; Suematsu Y; Nunes ACF; Jing W; Khazaeli M; Lau WL; Vaziri ND
Iran J Kidney Dis; 2019 Mar; 13(2):98-104. PubMed ID: 30988246
[TBL] [Abstract][Full Text] [Related]
6. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
8. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
[TBL] [Abstract][Full Text] [Related]
9. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
[TBL] [Abstract][Full Text] [Related]
10. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
David V; Martin A; Isakova T; Spaulding C; Qi L; Ramirez V; Zumbrennen-Bullough KB; Sun CC; Lin HY; Babitt JL; Wolf M
Kidney Int; 2016 Jan; 89(1):135-46. PubMed ID: 26535997
[TBL] [Abstract][Full Text] [Related]
12. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
[TBL] [Abstract][Full Text] [Related]
13. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease.
Hanudel MR; Czaya B; Wong S; Jung G; Chua K; Qiao B; Gabayan V; Ganz T
Sci Rep; 2022 Apr; 12(1):6695. PubMed ID: 35461329
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
16. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Nand N; Giri K; Jain D
J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
[TBL] [Abstract][Full Text] [Related]
17. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
[TBL] [Abstract][Full Text] [Related]
18. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
[TBL] [Abstract][Full Text] [Related]
20. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
